£6m Influenza HCT contract signed

Summary by AI BETAClose X

hVIVO plc has secured a £6 million contract to conduct a human challenge trial for a clinical-stage biopharmaceutical company, evaluating a monoclonal antibody for respiratory viral diseases. This trial, utilizing hVIVO's Influenza Human Challenge Study Model, will commence in 2026 with revenue recognized across 2026 and 2027, significantly enhancing the company's revenue visibility. The study will be conducted at hVIVO's facilities in Canary Wharf, with participant recruitment managed by FluCamp and laboratory work handled by hVIVO's specialist virology lab.

Disclaimer*

Companies

Hvivo (HVO)
UK 100

Latest directors dealings